Avant Diagnostics appointed Rajesh Shrotriya and Andy Delao to its board of directors.
Shrotriya, the former CEO and chairman of Spectrum Pharmaceuticals, has more than four decades of experience in medicine, first as a physician and then as a pharmaceutical industry executive. Under his leadership, Spectrum identified, developed, and commercialized several anti-cancer drugs. Prior to joining Spectrum, Shrotriya was executive vice president and chief scientific officer of SuperGen and chief medical officer of MGI Pharma.
Andy Delao is the senior director of marketing for Accuray, a radiation oncology technology company. He spent more than 8 years at GE Healthcare, where he held multiple roles assisting in developing and leading its Oncology Solutions Organization product marketing for the molecular imaging business.